Application of Botulinum Neurotoxin in Headache or Facial Pain Disorders
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 191
Special Issue Editor
Special Issue Information
Dear Colleagues,
The story of botulinum toxin in migraine care is one of clinical observation leading to scientific discovery. In the early 1990s, clinicians noted that patients receiving botulinum toxin for cosmetic indications often reported unexpected improvement in their headache symptoms. What began as anecdotal evidence evolved into a rigorous program of research that ultimately established botulinum toxin as the first non-oral preventive therapy approved for chronic migraine.
Since its approval, botulinum toxin has reshaped the preventive treatment landscape, offering an important alternative for patients who are unable to tolerate or do not respond adequately to conventional oral therapies. Its emergence has also deepened our understanding of migraine as a disorder of dysfunctional pain processing rather than solely a vascular phenomenon.
This Special Issue explores the evolution of neurotoxins in migraine treatment from early observations to contemporary clinical practice. We examine current insights into migraine pathophysiology and the mechanisms by which neurotoxins modulate peripheral and central pain pathways to produce sustained clinical benefit. In addition, we review the safety profile, durability of response, and long-term outcomes associated with botulinum toxin therapy in patients living with migraine.
Dr. Hope Lorraine O’Brien
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-oral preventive therapies
- chronic migraine
- botulinum toxin
- migraine prevention
- neurotoxins
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
